AI

#AI #Life sciences #Pistoia Alliance #R&D

Use of AI in drug R&D limited in life sciences, survey says 

The use of artificial intelligence is widespread across life sciences organisations but its use in drug research and development is limited, analysis finds.  Research by The Pistoia Alliance, a not-for-profit life sciences advocacy group, shows 30% of life sciences professionals say their organisation has implemented an enterprise-wide AI… Read More

#News

AI concept image
#AI #AI / data analytics / healthtech / informatics #Antibodies #Drug discovery

The structural data bottleneck in AI antibody discovery

Dan Benjamin, Co-Founder & Chief Technology Officer of Immuto Scientific, examines why limited antibody–antigen co-structure datasets may be constraining AI model performance—and how high-throughput structural generation could reshape the field. Artificial intelligence now plays a central role in antibody discovery. Machine learning models assist in sequence design, paratope prediction, affinity… Read More

#Exclusive Content

T cells
#AI #Automation / robotics #Oncology #T cell engagers

How AI and robotics designed new cancer therapies

The latest episode of the DDW ‘In Conversation With’ series is available to listen to below. This week, Bruno Quinney speaks to Angus Sinclair, Chief Scientific Officer at LabGenius Therapeutics. LabGenius is a biotech using AI and robotics to design new cancer therapies, and in vivo efficacy data reveals… Read More

#Featured Podcasts #Podcasts

#AI #Chemify #Drug discovery

Chemify’s drug discovery platform validated by papers

A platform helping drug discovery companies take a novel concept to makeable compound has been validated in three academic papers.  Chemify says its Chemputation platform, which integrates AI- and ML-driven molecular discovery and automated robotic synthesis, has been validated as a new paradigm for how small molecule-drugs and materials are discovered, designed and manufactured. … Read More

#News

Neurons in a brain with Alzheimer's disease
#AI #Alzheimer's #Stanford University

AI-powered ‘co-scientist’ wins prestigious Alzheimer’s prize 

Developers of an AI-powered ‘co-scientist’ have been awarded the $1 million Alzheimer’s Insights AI Prize.  Mount Sinai scientists, led by Dr Kuan-lin Huang, won the prize for developing Biomni-AD, an advanced AI-powered ‘co-scientist’ designed to dramatically reduce the time required to generate scientific insights from complex biomedical data.  Biomni-AD… Read More

#News

Clinical trial
#AI #Clinical trials #ICON

Partnership set to make therapies ‘reach patients sooner’ 

A new partnership could accelerate clinical trials and bring therapies to patients sooner.  Clinical research organisation ICON has partnered with Advarra to introduce a new ‘research-ready’ site network model for clinical trials, set to address major bottlenecks.  The partnership will integrate ICON’s global clinical trial solutions and… Read More

#News

#AI #Oncology #Precision medicine

Collaboration to advance precision oncology therapy 

Oncology company One-carbon Therapeutics has entered a strategic collaboration with precision medicine company Tempus AI to advance precision oncology development.  The collaboration will leverage Tempus’ proprietary, de-identified multimodal database and bioinformatics knowledge to advance molecular insights supporting the clinical development of TH9619.  TH9619, developed by One-carbon Therapeutics, is a first-in-class,… Read More

#Business & Investment #News

#AI #Genomics #PacBio

Genomics initiative could boost AI-designed therapeutics 

A new initiative is set to generate and model biological data at the trillion-gene scale, paving the way to scale AI-designed therapeutics.  The Trillion Gene Atlas, developed by Basecamp Research in collaboration with Anthropic, Ultima Genomics, PacBio, and NVIDIA AI infrastructure aims to expand known evolutionary genetic diversity… Read More

#News

#AI #Antibody discovery workflow #Antiverse #Deep Science Ventures

How generative AI is rewriting the rulebook for antibody drug discovery

Dr Kerstin Papenfuss, Deep Science Ventures, and Ben Holland, Antiverse, discuss how generative AI is helping advance antibody discovery.  The therapeutic antibody, once 'the next big thing,' has matured into a cornerstone of modern medicine, standing alongside small molecules as a staple of drug development. Yet, while artificial intelligence (AI) has dramatically… Read More

#Exclusive Content

#AI #Drug discovery #Women's health

Partnership to develop treatments for gynaecological diseases 

Tejin Pharma has partnered with pharmaceutical company Aska Pharmaceutical to develop treatments for gynaecological diseases.  As per the agreement, the companies will collaborate to accelerate the early-stage drug discovery process aimed at identifying innovative therapeutic candidates.   The companies intend to develop novel small-molecule drug candidates, a process which… Read More

#News

3d structure of the protein molecule
#AI #Drug design #Protein targets #Therapeutics

Galux raises $29m to advance AI-driven protein therapeutics 

Galux, a company using AI to drive drug design, has raised $29 million to support its protein therapeutics platform.  The Series B financing round brought together existing investors, including InterVest, DAYLI Partners, and PATHWAY Investment, with new investors Yuanta Investment, Korea Development Bank (KDB), SL Investment, NCORE Ventures, SneakPeek Investments, Korea Investment & Securities,… Read More

#Business & Investment #News

#AI #Automation #High throughput screening #SLAS2026

SLAS2026: AI, automation and high-throughput systems dominate 

From technology harnessing AI to launches of automation systems, DDW rounds up some of the biggest announcements from SLAS2026.      Carterra launches high-throughput SPR instrument    High-throughput technology provider Carterra launched its Carterra Vega High-Throughput Surface Plasmon Resonance (HT-SPR) instrument – the industry’s first 48-channel SPR platform.  Read more…    SPT… Read More

#News

#AI #Drug development #Legal action

Legal issues arising from the use of artificial intelligence in drug development

Adriana Tibbitts, Alison Lehner, Frank Rahmani, and Jason Kropp from law firm Sidley Austin talk about the legal risks that AI represents in drug discovery and development.      In today’s competitive pharmaceutical industry, drug developers are seeking tools to accelerate development and maximise the commercial potential of their products in a manner that conserves resources and enables them to prioritise their… Read More

#Exclusive Content

#AI #Charles River #Emulate #Lab automation #Promega #SLAS2026

SLAS2026: Day Two Round-Up

DDW covers some of the biggest announcements from the second day of SLAS2026.     Emulate showcases organ-chip platform at SLAS2026   Emulate has brought its AVA Emulation System to SLAS2026, showcasing the potential to accelerate drug development with a first-of-its-kind high-throughput organ-chip platform. Read more…   Charles River and… Read More

#News

#AI #Lab automation #SLAS2026

UniteLabs presents AI-ready lab automation system

UniteLabs has presented its Operating System at SLAS2026, promising to unlock AI-ready lab automation.  The Operating System replaces vendor-specific instruments and software with an open, Python-based infrastructure, giving lab automation engineers and scientists full control and transparency over their workflows. Use cases at launch included liquid handling and closed loop… Read More

#News

Artificial intelligence
#AI #Life sciences #SLAS2026

Cenevo launches AI agents to accelerate lab operations 

Cenevo has advanced towards agentic labs with the launch of two new AI agents.  The company, which specialises in lab management systems, automation, orchestration, data management and AI technology for life sciences, hopes the new agents will help scientists operate faster, smarter and with less manual overhead.  The first new agent,… Read More

#News